Secretome Therapeutics

About Secretome Therapeutics

Secretome Therapeutics is a pioneering company focused on developing novel therapies using neonatal cardiac progenitor cells (nCPCs) to address unmet medical needs in cardiovascular and inflammatory diseases, particularly heart failure.

Products & Services

STM-01:A lead drug derived from neonatal cardiac progenitor cells (nCPCs) with high potency for regenerative therapies, outperforming adult-derived stem cells.

STM-21:A secretome product derived from neonatal sources, ensuring minimal variability and supporting scalable stem cell-based therapies.

Investigational Medicine for HFpEF:An early-stage treatment for heart failure with preserved ejection fraction, currently in clinical trials.

Specialties

Neonatal Cardiac Progenitor Cells (nCPCs) Stem Cell-Based Therapies Cardiovascular Therapies Heart Failure Treatment Inflammatory Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Financing Round T: - FT: Financing Round	A: 20400000 MR: - FA: $20.4 million FAN: 20400000	D: 2024-11-25 FD: 2024-11-25	-
2	RT: SPV T: - FT: SPV	A: 1800000 MR: - FA: $1.8 million FAN: 1800000	D: 2024-09-17 FD: 2024-09-17	1 investors

Financing Round Latest

2024-11-25

$20.4M

SPV 2024-09-17

$1.8M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

V

Vinny Jindal

Co-founder, Board Member, President & CEO

M

Marshelle Smith

Chief Medical Officer

J

Jeff Masten

Senior Vice President, CMC Operations

S

Salman Bhai

Vice President, Clinical Development

M

Malika Pasha

Vice President, Clinical Operations

R

Rachana Mishra

Co-founder, Senior Director of CMC

View 23 more team members with Pro

Unlock Full Team Directory

Recent News